Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.

ABSTRACT: Although the successful clinical trials of immunotherapy show promising strategies for many cancers, its application in glioma has lagged in comparison with the progress seen in other cancers. Both isocitrate dehydrogenase (IDH) mutations and 1p/19q codeletions are critical molecular alterations affecting therapeutic response in lower-grade glioma (LGG). The systematic and comprehensive characterization of the immunological phenotypes with different molecular subtypes is key to improving our understanding and application of immunotherapies in LGG. Here, we collected the RNA-sequencing, somatic mutation, and clinical data from 1,052 patients from The Cancer Genome Atlas and Chinese Glioma Genome Atlas and stratified patients into three genetic subgroups: IDH mutations with 1p/19q codeletion

SUBMITTER: Lin W 

PROVIDER: S-EPMC8167204 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature